Results of international clinical trials with raloxifen;Resultats des etudes cliniques internationales du raloxifene

Annales d'Endocrinologie

Volumn 60, Issue 3, 1999, Pages 242-246

  Agnusdei, D ^a   Liu Leage S ^b   Augendre Ferrante, B ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE ATROPHY; BONE DENSITY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOT FLUSH; HUMAN; MENOPAUSE; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; ANIMAL; CLINICAL TRIAL; INTERNATIONAL COOPERATION; MULTICENTER STUDY; REVIEW;

ANIMALS; CLINICAL TRIALS; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MULTICENTER STUDIES; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0344980184     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. HAMMOND GB. Menopause and Hormone Replacement Therapy : An Overview. Obstet Gynaecol 1995 ; 87 : 2-15.
2. US Congress, Office of Technology Assessment. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Volume II : Evidence of Benefits, Risks and Costs. Washington, DC : US Government Printing Office, August 1995.
3. BARRETT-CONNOR E, BUSH TL. Estrogen and Coronary Heart Disease in Women. JAMA 1991 ; 265 : 1861.
4. The Writing Group for the PEPI Trial. Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women : the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995 ; 273 : 199-208.
5. UPTON GV. The Perimenopause : Physiologic Correlates and Clinical Management. J Reprod Med 1982 ; 27 : 1-27.
6. HULLEY SB, GRADY D, BUSH TL, FURBERG C, HERRINGTON D, RIGGS BL et al. Randomised Trial of Estrogen plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA 1998 ; 280 : 605-13.
7. BERESFORD SA, WEISS NS, VOIGT LF, MCKNIGHT B. Risk of Endomctrial Cancer in Relation to Use of Estrogen Combined with Cyclical Progcstagen Therapy in Postmenopausal Women. Lancet 1997 ; 1 : 458-61.
8. A Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and Hormone Replacement Therapy : Collaborative Reanalysis of Data from 51 Epidemiological Studies of 52,705 women with Breast Cancer and 108.411 Women without Breast Cancer. Lancer 1997 ; 350 : 1047-59.
9. BRYANT HU, DERE WH. Selective Estrogen Receptor Modulators : an Alternative to Hormone Replacement Therapy. Proc Soc Exp Biol Med 1998 ; 217 : 45-52.
10. BLACK LJ, SATO M, ROWLEY ER, MAGEE DE, BEKELE A. WILLIAMS DC, CULLINAN GJ, BENDELE R, KUFFMAN RF, BENSCH WR, FROLIK CA, TERMINE JD, BRYANT HU. Raloxifene (LY 139481 HCI) Prevents Bone Loss and Reduces Serum Cholesterol without Causing Uterine Hypertrophy in Ovariectomized Rats. J Clin Invest 1994 ; 93 : 63-9.
11. WAKELING AE, VALCACCIA B, NEWBOULT E, GREEN LR. Non-steroidal Antioestrogens - Receptor Binding and Biological Response in Rat Uterus, Rat Mammary Carcinoma and Human Breast Cancer Cells. J Steroid Biochem 1984 ; 20 : 111-20.
12. DELMAS PD, BJARNASON NH, MITLAK B, RAVOUX AC, SHAH AS, HUSTER WJ et al. Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women. N Eng J Med 1997 ; 337 : 1641-47.
13. BJARNASON NH, DELMAS PD, MITLAK B, SHAH AS, HUSTER WJ, DRAPER MW et al. Raloxifene Maintains Favourable Effects on Bone Mineral Density. Bone Turnover and Serum Lipids without Endometrial Stimulation in Postmenopausal Women. 3-year Study Results. Osteoporosis Int 1998 ; 8 : 11.
14. ETTINGER B, BLACK DM, CUMMINGS SR, GENANT HK, BLUER CC, LIPS P et al. Raloxifene Reduces the Risk of Incident Fractures : 24-month Interim Analyses. Osteoporosis Int 1998 ; 3 : 11.
15. EVANS G, BRYANT HU, MAGEE D. SATO M, TURNER RT. The Effects of Raloxifene on Tibia Histomorphometry in Ovariectomized rats. Endocrinology 1994 ; 134 : 2283-88.
16. WALSH BW, KULLER LH, WILD RA, PAUL S, FARMER M, LAWRENCE JB et al. Effects of Raloxifene on Serum Lipids and Coagulation factors in Healthy Postmenopausal Women. JAMA 1998 ; 279 : 1445-51.
17. CUMMINGS SR, NORTON L, ECKERT S, GRADY D, CAULEY J, KNICKERBOCKER R et al. Raloxifene Reduces the Risk of Breast Cancer and May Decrease the Risk of Endometrial Cancer in Postmenopausal Women. Two-year Findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Am Soc Clin Oncol 1998 ; 17 : 2a.
18. JORDAN VC, GLUSMAN J, ECKERT S, LIPPMNA M, POWLES T, COSTA A et al. Incident Primary Breast Cancers are Reduced by Raloxifene : Integrated Data from Multicenter Double-blind. Randomised Trials in 12,000 Postmenopausal Women. Am Soc Clin Oncol 1998 ; 17 : 122a.